Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative relugolix versus leuprorelin before laparoscopic myomectomy for uterine fibroids
jRCTs031210564Completed
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Jul 2022
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial in Fibromyoma (LM) comparing Relugolix group with Leuprorelin acetate group (2 arms). Primary endpoint: Intraoperative blood loss. Started Jul 2022; status: completed.
02
Drugs
tissue-plasminogen activatorleuprolide
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on jRCTs031210564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210564.